Tenofovir (TDF) is an effective and widely used treatment for both human immunodeficiency
virus (HIV) and hepatitis B virus infection. Although studies suggest that TDF has a low …

Tenofovir is an acyclic nucleotide analogue reverse‐transcriptase inhibitor structurally
similar to the nephrotoxic drugs adefovir and cidofovir. Tenofovir is widely used to treat HIV …

Objective: Compared with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF)
has been associated with improvement in markers of renal dysfunction in individual …

Background & Aims Tenofovir alafenamide, a phosphonate prodrug of tenofovir with greater
plasma stability than tenofovir disoproxil fumarate, provides efficient delivery of active drug …

Objectives: To evaluate the safety and efficacy of the novel tenofovir prodrug, tenofovir
alafenamide (TAF), as part of a single-tablet regimen (STR) for the initial treatment of HIV-1 …

Objectives: To evaluate the safety and efficacy of the novel tenofovir prodrug, tenofovir
alafenamide (TAF), as part of the first protease inhibitor–based single-tablet regimen (STR) …

Tenofovir disoproxil fumarate (TDF), the first nucleotidic inhibitor of HIV reverse transcription,
became available in 2001. It has been extensively used worldwide and is now the most …

Objective: Tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis decreases sexual
acquisition of HIV infection. We sought to evaluate the renal safety of TDF in HIV-uninfected …

Abstract Multidrug resistance protein 7 (MRP7), also known as ATP-binding cassette (ABC)
transporter subfamily C10 (ABCC10), is an ABC transporter that was first identified in 2001 …

Objective In this study, data regarding epidemiology, risk factors, pathogenesis and outcome
of tenofovir-induced nephrotoxicity will be reviewed, and current and future approaches for …